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Dithiothreitol (DTT) and 2-mercaptoethanol (2-ME) are 
sulfhydryl compounds that can be used to treat serum or plasma 
to denature IgM antibody reactivity. By using sulfhydryl agents, 
IgG and IgM antibodies can be separated, the relative amount 
of IgM and IgG antibodies can be determined, and the risk of 
hemolytic disease of the fetus and newborn can be assessed. 
Immunohematology 2018;34:135–139.
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Principle
An IgM molecule is a 19S pentamer in which disulfide 
bonds hold the five immunoglobulin subunits together; a J chain 
joins them. These intersubunit disulfide bonds and J chain are 
more sensitive to reduction with sulfhydryl reagents than the 
interchain (heavy and light chains) disulfide bonds that are in 
both IgM and IgG molecules. Dissociating the IgM pentamer 
into its single subunits helps to identify the immunoglobulin 
class of an antibody and determine its potential for causing 
hemolytic disease of the fetus and newborn (HDFN).1 
Sulfhydryl groups, or thiols, such as dithiothreitol (DTT) 
and 2-mercaptoethanol (2-ME), are carbon-based molecules 
bound to a sulfur and hydrogen atom (R-SH). These thiols 
can reduce disulfide bonds (R-SS-R) in proteins and can 
be oxidized to form disulfide bonds (R -SH + R -SS-R  ↔ 
R -SS-R  + R -SH).2 
Reactivity of IgM antibodies can be removed through the 
dissociation of the intersubunit disulfide bonds and J chains 
(Fig. 1). Reactivity of IgG antibodies may be enhanced through 
the reduction of disulfide bonds in the hinge region, allowing 
for binding of antigen sites further apart.1
In 1957, Deutsch and Morton2 described the use 
of 2-mercaptoethanol (2-ME) to dissociate human 
macroglobulins, which reaggregated into different molecular 
components after dialysis to remove the sulfhydryl 
compound. The use of sulfhydryl-blocking agents prevented 
the reaggregation.2 
Use of dithiothreitol (DTT) is generally preferred over 
2-ME. DTT is better at maintaining reduction of disulfide 
bonds, is not oxidized by air, is a water-soluble solid, and has 
a milder odor.3 DTT is a dithiol; it has two reactive sulfhydryl 
groups (R-SH) rather than one, like 2-ME. Pirofsky and 
Rosner4 stated that the additional sulfhydryl group allows for 
better reduction of disulfide bonds. Effectiveness of DTT was 
comparable to 2-ME, having identical results in 97 percent 
of sera tested, and DTT required a weaker concentration. 
Furthermore, the cyclic structure of the oxidized form of DTT 
with its two hydroxyl groups (-OH) on the middle carbons 
allow for more stability and milder odor (Figs. 2 and 3).4 
Freeman et al.5 did report more effective dissociation of IgM 
antibodies with 0.2 M 2-ME than with 0.01 M DTT when 
comparing titration results.
Indications
Determination of the immunoglobulin class of an antibody 
to a red blood cell (RBC) antigen aids in the assessment of risk 
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• PBS (pH 7.3–7.4)






• IgG antibody (optional)
For DTT and 2-ME:
• Test tubes
• Pipettes
• 37°C water bath/incubator
• Calibrated timer
• Calibrated serologic centrifuge
• Agglutination viewer
For 2-ME only:
• Wooden applicator stick (optional)
• Four to six 10-inch lengths of 
cellulose dialysis tubing (optional)
• Four to six 1-liter beakers (optional)
DTT = dithiothreitol; 2-ME = 2-mercaptoethanol; PBS = phosphate-
buffered saline; RBCs = red blood cells.
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of HDFN in pregnant women, since only IgG antibodies cross 
the placenta. Some antibodies to RBC antigens, like anti-M, 
have been described in case reports as being composed of IgM, 
IgG, or both classes. Therefore, assessment of HDFN risk may 
require determination of immunoglobulin class. For example, 
Mohd Nazri et al.6 reported a severe case of recurrent fetal loss 
(G10P2+7) due to anti-M. Smith and Beck7 used DTT treatment 
to determine whether examples of saline-agglutinating anti-M 
were IgM or IgG, and they found that 78 percent of these 
anti-M retained reactivity after treatment. Selected samples 
in this group were confirmed to be IgG antibodies by column 
chromatography. Likewise, determining that an antibody is 
solely of the IgM class can reduce the number of interventions 
during pregnancy. Jain et al.8 reported that a non-hydropic 
baby was born to a woman of the Bombay phenotype, whose 
anti-H was nonreactive after DTT treatment. 
Sulfhydryl treatment of plasma allows for the titration 
of IgG antibodies when both IgM and IgG antibodies are 
present.9 This scenario allows relative amounts of IgG versus 
IgM antibody to be determined.10
Reesink et al.11 compared titers of untreated, neutralized, 
and 2-ME–treated group O maternal sera to evaluate the 
relative amount of IgM and IgG ABO antibodies and found no 
difference in the titer results, concluding that the antibodies 
were solely IgG. Additionally, DTT or 2-ME treatment of 
plasma or serum can be used to avoid IgM antibody reactivity 
that may mask the presence of an IgG antibody.
Materials
The optimal concentration of DTT for inactivation of 
IgM antibodies was determined by Freedman et al.5 to be 
0.01 M; greater concentrations of DTT (e.g., 0.02 M DTT) 
were ineffective, since they caused the serum to gel during 
incubation.
DTT may be purchased as a water-soluble solid or as a 
solution. Preparation of 0.01 M DTT from the solid reagent is 
performed by dissolving 0.154 g of DTT in 100 mL phosphate-
buffered saline (PBS), pH 7.3.10 Preparation of the liquid DTT 
reagent at a 0.2-M concentration requires a dilution by adding 
2 mL of 0.2 M DTT to 38 mL PBS to obtain 0.01 M DTT.
Frozen storage (–20°C) of 0.01 M DTT prepared with 
PBS is recommended to maintain reducing ability. Olson 
et al.9 observed that freezing DTT caused no loss of reactivity 
over several months, but refrigerated storage (4°C) resulted in 
deterioration of DTT in less than 1 week. Pirofsky and Rosner4 
maintained stability of 0.01 M DTT prepared with isotonic 
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Procedural Steps for Preparation
1. Mix equal volumes of plasma/serum with 0.01 M DTT or 0.2 M 
2-ME in a test tube (TEST) for patient and each control.
2. Mix equal volumes of plasma/serum with PBS in a test tube 
(DILUTION CONTROL) for patient and each control.
3. For DTT: Incubate both sets of tubes at 37°C for 30–60 
minutes.
4. For 2-ME: Incubate both sets of tubes at 37°C for 15 minutes.
5. For 2-ME: Optional step if testing with anti-IgG: Dialyze 2-ME–
treated plasma/serum and dilution control.
a. Add TEST to dialysis tubing (knotted at one end) and then 
knot the open end for patient and each control.
b. Add DILUTION CONTROL to dialysis tubing (knotted at 
one end) and then knot the open end for patient and each 
control.
c. Add each dialysis tubing to its own beaker filled with PBS; 
allow to dialyze overnight.
d. Remove dialysis tubing and blot dry.
e. Cut each tubing and transfer contents to a clean test 
tube.
Compiled from Freedman et al.5 and Fung et al.12
DTT = dithiothreitol; 2-ME = 2-mercaptoethanol; PBS = phosphate-
buffered saline.
Procedural Steps for Testing
1. Add four drops of treated plasma/serum to one drop 
appropriate reagent RBCs (TEST) for patient and each control.
2. Add four drops of control plasma/serum to one drop 
appropriate reagent RBCs (CONTROL) for patient and each 
control.
3. Incubate at room temperature for 30 minutes.
4. Centrifuge and read for agglutination.
5. Incubate at 37°C for 30–60 minutes.
6. Centrifuge and read for agglutination.
7. For incomplete antibodies, wash four times with saline and add 
two drops anti-IgG.
8. Centrifuge and read for agglutination.
9. Add IgG-coated RBCs to negative reactions.
Titration Studies
1. Prepare master serial dilutions of TEST and DILUTION 
CONTROL in PBS.
2. Add specified volume of each dilution of TEST and DILUTION 
CONTROL to labeled tube.
3. Add appropriate reagent RBCs.
4. Incubate at room temperature for 30 minutes.
5. Centrifuge and read for agglutination.
6. Incubate at 37°C for 1 hour.
7. Centrifuge and read for agglutination.
8. For incomplete antibodies, wash four times with saline, and 
add two drops anti-IgG.
9. Centrifuge and read for agglutination.
10. Add IgG-coated RBCs to negative reactions.
Compiled from Pirofsky and Rosner4 and Olson et al.9
RBCs = red blood cells; PBS = phosphate-buffered saline.
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saline for up to 6 months when refrigerated or frozen, but 
when using DTT prepared with PBS, the reducing ability was 
lost within 14 days when refrigerated.
2-ME may be purchased in a solution. Preparation of 0.2 
M 2-ME requires a dilution by adding 0.2 mL of 1 M 2-ME to 
0.8 mL PBS, pH 7.4.
Preparation
DTT-Treated Plasma/Serum
In a test tube labeled “TEST,” add an equal volume of 0.01 
M DTT to the plasma or serum to be evaluated. In another test 
tube labeled “DILUTION CONTROL,” add an equal volume 
of PBS to the plasma or serum. Mix the tubes and allow them 
to incubate at 37°C for 30–60 minutes, not to exceed 2 hours. 
Control samples should be treated and tested in parallel (see 
Quality Control).12
2-ME–Treated Plasma/Serum
In a test tube labeled “TEST,” add an equal volume of 0.2 
M 2-ME to the plasma or serum to be evaluated. In another test 
tube labeled “DILUTION CONTROL,” add an equal volume of 
PBS to the plasma or serum. Mix the tubes and allow them to 
incubate at 37°C for 15 minutes.5,13 An alternative method uses 
0.1 M 2-ME and incubation at 37°C for 1–2 hours.4,13 Control 
samples should be treated and tested in parallel.
Freedman et al.5 observed false-positive reactions when 
2-ME–treated plasma was not dialyzed, but Rosner et al.14 
found the validity of the test to not be affected by eliminating 
the dialysis step. The dialysis procedure, if desired, consists of 
Fig. 2 Reduced and oxidized form of dithiothreitol (DTT).
Reduced form of DTT Oxidized form of DTT
Fig. 3 Reduced and oxidized form of 2-mercaptoethanol (2-ME).
Reduced form of 2-ME Oxidized form of 2-ME
Fig. 1 Reduction of IgM by dithiothreitol.
138 IMMUNOHEMATOLOGY, Volume 34, Number 4, 2018
adding each sample to a segment of dialysis tubing. One end 
of the dialysis tubing should be tightly secured by knotting 
or tying before adding the sample. Once the sample has been 
added to the dialysis tubing, the other end should be secured 
by tightly knotting or tying. Each dialysis tube is suspended in 
its own beaker containing a large volume of PBS and allowed to 
dialyze overnight with several changes of PBS.13 After dialysis, 
each dialysis tubing should be removed from the beaker and 
blotted dry, and the contents should be transferred to clean 
test tubes.14
Procedure
Test the DTT-treated or 2-ME–treated plasma or serum 
with reagent RBCs in appropriate serologic tests. For antibody 
identification panels, four drops of treated and control 
plasma should be mixed with one drop of appropriate RBCs.5 
Incubation for 30 minutes at room temperature and/or 30–60 
minutes at 37°C may be performed depending on the initial 
phase of reactivity before treatment. If the antibody was 
reactive at 37°C or the antihuman globulin (AHG) phase, the 
treated and control plasmas should be washed four times after 
incubation at 37°C and observed for carry-over agglutination 
before the addition of anti-IgG. Add two drops of anti-IgG. 
Centrifuge the tubes, and read for agglutination. Add IgG-
coated RBCs to all nonreactive tests.
Titration
For titrations studies, master serial saline dilutions are 
prepared for both the treated plasma and dilution control as 
per an in-house titration procedure. The specified volume 
of each dilution is mixed with an appropriate volume of 
reagent RBCs.4 Incubate all tubes at room temperature (30 
minutes) and/or 37°C (1 hour), centrifuge, and read for direct 
agglutination. Continue through to the AHG phase of testing, 
using anti-IgG after washing the RBCs four times.4,9
Quality Control
A dilution control should always be tested with DTT-
treated or 2-ME–treated plasma or serum to ensure that 
the reduction or removal of antibody reactivity is not due to 
dilution of the antibody.12 Control samples should be treated 
and tested in parallel.12,13
An IgM antibody control should be included in the DTT 
or 2-ME treatment with a dilution control to ensure that the 
sulfhydryl reagent is adequately reducing the disulfide bonds 
and removing the IgM antibody reactivity.12 This antibody 
can be selected based on its reactivity in immediate spin tests. 
An IgG antibody control should be performed if testing will 
proceed to the AHG phase to demonstrate that these antibodies 
remain reactive after treatment.
Antigen-negative RBCs should be included when testing 
2-ME–treated plasma by indirect antiglobulin to detect false-
positive reactivity, which was described by Freedman et al.5 
when 2-ME–treated plasma was not dialyzed.
Interpretation
The interpretation of the test depends on the presence and 
strength of the reactivity when the controls react as expected 
(Table 1). The sample may be concluded as having only IgM 
class antibody present if the DTT- or 2-ME–treated plasma 
or serum has no reactivity and the dilution control remains 
reactive.
The sample may be interpreted as having IgG antibody or 
a mixture of IgG and IgM antibodies present if both the treated 
plasma or serum and the dilution control remain reactive.12,13 
Titration studies may be performed to determine the relative 
amount of each immunoglobulin class. If the titer of the treated 
plasma or serum is the same as that of the dilution control, it 
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(DTT or 2-ME + plasma/serum)
Dilution Control 0
(PBS + plasma/serum)
Adapted from Fung et al.12
* The absolute titer endpoints will vary depending on the specific antibody 
tested. The relationship between the titer endpoint of the treated plasma as 
compared with that of the dilution control is the critical determination of the 
immunoglobulin class(es) present.
DTT = dithiothreitol; 2-ME = 2-mercaptoethanol; PBS = phosphate-
buffered saline.
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can be concluded that there is only IgG antibody present. If 
the dilution control has a higher titer than the DTT- or 2-ME–
treated plasma or serum, it can be concluded that there is a 
mixture of IgG and IgM antibodies or partial inactivation of 
IgM antibodies.12,13
The test is considered invalid if the dilution control is 
nonreactive, indicating that the antibody was diluted and is 
too weak to show antibody reactivity.12,13 The test should also 
be considered invalid if the IgM and/or IgG control antibodies 
treated and tested in parallel do not give the expected results.
Limitations
Gelling of the serum or plasma may occur during 
sulfhydryl treatment when the concentration of DTT or 2-ME 
is too high or the test has been incubated too long.5 Gelled 
samples should not be tested, since the overtreatment may 
result in denaturation of all serum proteins, including IgG 
antibodies.12
Sulfhydryl reagents may also weaken Kell system antigens 
if the reagent is not removed by dialysis before testing, because 
the structure of the Kell glycoprotein has disulfide bonds. It is 
recommended that thiol-treated plasma or serum is not used 
when investigating KEL blood group system antibodies, since 
false-negative or lower titer results may occur.12
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